Clinical trials: Thromboembolic Disorders
Venous Thromboembolism
Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005
The purpose of this study is to describe the incidence of thromboembolic events in relation to pregnancy and when in pregnancy and the puerperal period.
- Trial name
- NCT01176305
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hillerod Hospital, Denmark
Venous Thromboembolic Disease, Post Thrombotic Syndrome
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE
The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic…
- Conditions
- Venous Thromboembolic Disease, Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Quality of Life
- Trial name
- HOKUSAIpostVTE (NCT04007653)
- Testing
- Observation
- Where
- Netherlands
- Volunteers
- 1,200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Embolism
Pulmonary Endarterectomy Guided by CT Scanning for Patients With Chronic Thromboembolic Pulmonary Hypertension----PEACT
This study is a effectiveness study of the application of high-definition enhanced computed-tomography for patients with chronic thromboembolic pulmonary hypertension(CTEPH).The patients with CTEPH was randomized into 2…
- Trial name
- PEACT (NCT03795740)
- Testing
- 3-D CT scanning
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sheng Liu
Thromboembolic Complications
Thrombelastography Based Dosing of Enoxaparin
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs.
- Trial name
- NCT00990236
- Testing
- Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Oregon Health and Science University
Venous Thromboses, Thromboembolic Disease
Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative…
- Conditions
- Venous Thromboses, Thromboembolic Disease, Neutrophil Extracellular Trap Formation, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- CLODETTE (NCT05711173)
- Testing
- Additional blood sampling
- Where
- 7 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Bordeaux
Hypertension, Pulmonary
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life…
- Trial name
- CAPTURE (NCT02545465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Bayer
Acute Lymphoblastic Leukemia
Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children.
Acute lymphoblastic leukemia is the most common malignancy of the child. Current therapeutic strategies allow healing of over 80% of children. However these treatments are associated with toxicity, with a mortality of 1-2%.
- Trial name
- THROMBLEUKEMIA (NCT02862652)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 24 people
- Sponsor
- CHU de Reims
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)
- Trial name
- CPETPH (NCT02061787)
- Testing
- balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Myocardial Infarction
RElevance of Biomarkers for Future Risk of Thromboembolic Events in UnSelected Post-myocardial Infarction Patients
The study is an open, single center, observational study at the Cardiology Dept at Uppsala University Hospital. The number of patients included will be 410.
- Trial name
- REBUS (NCT01102933)
- Where
- Sweden
- Volunteers
- 425 people
- Sponsor
- Uppsala University
Heart Failure
Tissue Factor Expression in Stage C Heart Failure
Monocyte tissue factor (TF) was characterized in Class C heart failure (HF) vs. 25 age-matched volunteers. TF was 2.9 fold higher (p < 0.001) in HF patients vs. controls.
- Trial name
- TFHF (NCT00935740)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Utah
Hypertension, Pulmonary
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies [NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177…
- Trial name
- PLATYPUS (NCT05179876)
- Testing
- Macitentan, Selexipag, Macitentan/Tadalafil FDC
- Where
- 45 sites in Belarus, Belgium and 11 more
- Volunteers
- 280 people
- Sponsor
- Actelion
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim